Anti-FBN2/ CCA/ DA9 functional antibody

Anti-FBN2/ CCA/ DA9 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to FBN2/FBN2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0209-Ab-1/ GM-Tg-hg-SE0209-Ab-2Anti-Human FBN2 monoclonal antibodyHuman
GM-Tg-rg-SE0209-Ab-1/ GM-Tg-rg-SE0209-Ab-2Anti-Rat FBN2 monoclonal antibodyRat
GM-Tg-mg-SE0209-Ab-1/ GM-Tg-mg-SE0209-Ab-2Anti-Mouse FBN2 monoclonal antibodyMouse
GM-Tg-cynog-SE0209-Ab-1/ GM-Tg-cynog-SE0209-Ab-2Anti-Cynomolgus/ Rhesus macaque FBN2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0209-Ab-1/ GM-Tg-felg-SE0209-Ab-2Anti-Feline FBN2 monoclonal antibodyFeline
GM-Tg-cang-SE0209-Ab-1/ GM-Tg-cang-SE0209-Ab-2Anti-Canine FBN2 monoclonal antibodyCanine
GM-Tg-bovg-SE0209-Ab-1/ GM-Tg-bovg-SE0209-Ab-2Anti-Bovine FBN2 monoclonal antibodyBovine
GM-Tg-equg-SE0209-Ab-1/ GM-Tg-equg-SE0209-Ab-2Anti-Equine FBN2 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0209-Ab-1/ GM-Tg-hg-SE0209-Ab-2; GM-Tg-rg-SE0209-Ab-1/ GM-Tg-rg-SE0209-Ab-2;
GM-Tg-mg-SE0209-Ab-1/ GM-Tg-mg-SE0209-Ab-2; GM-Tg-cynog-SE0209-Ab-1/ GM-Tg-cynog-SE0209-Ab-2;
GM-Tg-felg-SE0209-Ab-1/ GM-Tg-felg-SE0209-Ab-2; GM-Tg-cang-SE0209-Ab-1/ GM-Tg-cang-SE0209-Ab-2;
GM-Tg-bovg-SE0209-Ab-1/ GM-Tg-bovg-SE0209-Ab-2; GM-Tg-equg-SE0209-Ab-1/ GM-Tg-equg-SE0209-Ab-2
Products NameAnti-FBN2 monoclonal antibody
Formatmab
Target NameFBN2
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-FBN2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0209-Ag-1Recombinant multi-species FBN2/ CCA/ DA9 protein


    Target information

    Target IDGM-SE0209
    Target NameFBN2
    Gene ID2201,14119,689008,704896,481491,101088809,540017,100073031
    Gene Symbol and SynonymsCCA,DA9,EOMD,FBN2,Fib-2,mKIAA4226,sne,sy
    Uniprot AccessionP35556
    Uniprot Entry NameFBN2_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000138829
    Target ClassificationN/A

    The target: FBN2, gene name: FBN2, also named as CCA, DA9, EOMD. The protein encoded by this gene is a component of connective tissue microfibrils and may be involved in elastic fiber assembly. Mutations in this gene cause congenital contractural arachnodactyly. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.